Azelia Brown, Mercer University College of Pharmacy
Elevated blood levels of low density lipoproteins (LDL) are stated to increase risk for atherosclerotic cardiovascular events. Statins are the reported agent of choice with proven efficacy, though variation in therapeutic response may require the use of additional therapy. 
Serine protease proprotein convertase subtilisin–kexin type 9 (PCSK9) is an enzyme that promotes the degradation of LDL receptors which reduces LDL re-uptake and leads to increased LDL levels.  Some PCSK9 agents are monoclonal antibodies that work by sequestering PCSK9 and preventing it from binding to LDL receptors. Inclisiran interferes with ribonucleic acid, reducing the hepatic production PCSK9.